var data={"title":"Ursodeoxycholic acid (ursodiol): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ursodeoxycholic acid (ursodiol): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7131?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ursodeoxycholic-acid-ursodiol-drug-information\" class=\"drug drug_general\">see &quot;Ursodeoxycholic acid (ursodiol): Drug information&quot;</a> and <a href=\"topic.htm?path=ursodeoxycholic-acid-ursodiol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ursodeoxycholic acid (ursodiol): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232635\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Actigall;</li>\n      <li>Urso 250;</li>\n      <li>Urso Forte;</li>\n      <li>Ursodiol+SyrSpend SF PH4</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232636\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dom-Ursodiol Cl;</li>\n      <li>PHL-Ursodiol C;</li>\n      <li>PMS-Ursodiol C;</li>\n      <li>Urso;</li>\n      <li>Urso DS</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062826\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gallstone Dissolution Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445212\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Biliary atresia, status post-Kasai procedure:</b> Limited data available: Term neonates: Oral: 10 to 20 mg/kg/day in 2 to 3 divided doses. Dosing based on small prospective and retrospective trials of neonates and very young infants that included ursodiol as part of a multidrug regimen designed to reduce the risk of cholangitis (Kelly 2007; Meyers 2003; Nittono 1989; Stringer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition-induced cholestasis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Treatment:</i> Limited data available; efficacy results variable: Oral: 30 mg/kg/day in 3 divided doses; dosing based on two retrospective studies of a total 18 neonates with cholestasis who received 10 to 30 mg/kg/day of ursodiol (Chen 2004; Levine 1999); neonates who were treated with ursodiol had a significantly shortened duration of cholestasis (62.8 &plusmn; 10.7 days vs 92.4 &plusmn; 8.8 days) and decreased peak direct bilirubin (5.3 &plusmn; 0.6 vs 8.7 &plusmn; 1.1 mg/dL) compared to no treatment (Chen 2004); improvement of bilirubin was seen after 2 weeks and 50% of patients saw a decrease in transaminases (Levine 1999). In the largest retrospective trial (n=64) neonates receiving ursodiol (mean dose: 24.9 mg/kg/day) had a significantly prolonged resolution of cholestasis compared to controls (median: 79 vs 50 days); authors attribute this to smaller, more premature patients in the treatment group and possibly due to a delay in treatment with ursodiol (time from onset of cholestasis to treatment: Median: 24 days) (Thibault 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Prevention:</i> Limited data available: Oral: 20 mg/kg/day in 4 divided doses. Dosing based on a prospective, randomized, controlled study of neonates who received parenteral nutrition for at least 12 days and were receiving &lt;75 mL/kg/day of enteral feeds by day of life 14; 24 neonates (GA: Median: 28 weeks, range: 24 to 32 weeks; birth weight: mean: 1,038 &plusmn; 221 g) received ursodiol at 20 mg/kg/day in 4 divided doses starting at DOL 14; results showed ursodiol was more effective at preventing cholestasis compared to erythromycin or placebo (Gokmen 2012). Another double-blind, placebo-controlled study of premature neonates (Ursodiol group: n=15; birth weight: Mean: 1,646.4 g; GA: mean: 31.9 weeks) requiring parenteral nutrition during the first few days of life reported a dose escalation regimen; ursodiol was initiated at 5 mg/kg/day in 4 divided doses beginning on day of life 3 with initiation of parenteral nutrition; increase dose to 10 mg/kg/day in 4 divided doses with initiation of enteral feeding; increase dose to 20 mg/kg/day in 4 divided doses when full enteral feedings reached. Neonates given ursodiol experienced earlier achievement of full feeds and slight decrease of fecal fat excretion (Arslanoglu 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062819\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ursodeoxycholic-acid-ursodiol-drug-information\" class=\"drug drug_general\">see &quot;Ursodeoxycholic acid (ursodiol): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Biliary atresia, status post-Kasai procedure:</b> Limited data available: Infants and Children: Oral: 10 to 20 mg/kg/day in 2 to 3 divided doses. Dosing based on small prospective and retrospective trials that included ursodiol as part of a multidrug regimen designed to reduce the risk of cholangitis (Kelly 2007; Meyers 2003; Nittono 1989; Stringer 2007; Yamashiro 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pruritus secondary to cholestasis:</b> Limited data available: Infants, Children, and Adolescents: Oral: 15 to 20 mg/kg/day once daily or in divided doses twice daily; doses up to 30 mg/kg/day may be necessary in some patients (Dinler 1999; Narkewicz 1998; Kliegman 2016). Dosing based on long-term (2.5 years), open-label, crossover trial of 13 patients (ages 2 to 27 years) with intrahepatic cholestasis; six of the 13 patients had symptomatic improvement in pruritus (Narkewicz 1998). In another study of 24 pediatric patients (1.5 to 15 years) treated with ursodiol, all patients experienced improvement in pruritus and 16.7% had complete resolution of pruritus (Dinler 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cystic fibrosis-related liver disease:</b> Limited data available: Infants, Children, and Adolescents: Oral: Limited data available:  Initial: 20 mg/kg/day in 2 divided doses, reported range: 10 to 30 mg/kg/day in divided doses; individualize dose based on patient response (Columbo 1990; Debray 2011; Lepage 1997; Sokol 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Parenteral nutrition-induced cholestasis, treatment:</b> Limited data available: Infants and Children: Oral: 30 mg/kg/day in 3 divided doses (Chen 2004; De Marco 2006; Spagnuolo 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gallstone dissolution (Actigall):</b> Oral: 8 to 10 mg/kg/day in 2 to 3 divided doses; use beyond 24 months is not established</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gallstone prevention (Actigall):</b> Oral: 300 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary biliary cirrhosis (Urso, Urso Forte): </b>Oral: 13 to 15 mg/kg/day in 2 to 4 divided doses (with food)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232618\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Actigall: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ursodiol+SyrSpend SF PH4: 30 mg/mL (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urso 250: 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Urso Forte: 500 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232603\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50027245\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=ursodeoxycholic-acid-ursodiol-drug-information\" class=\"drug drug_general\">see &quot;Ursodeoxycholic acid (ursodiol): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Ursodiol+SyrSpend SF PH4 oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062829\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Do not administer with aluminum-based antacids or bile acid sequestrants. If aluminum-based antacids are needed, administer 2 hours after ursodiol; administer ursodiol 5 hours or more after bile acid sequestrants (Rust 2000). Urso Forte can be split into halves for appropriate dosage; do not chew. Urso and Urso Forte should be taken with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232632\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Actigall:  Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urso: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urso Forte: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). When broken in half, scored Urso Forte 500 mg tablets maintain quality for up to 28 days when kept in current packaging and stored at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Split tablets should be stored separately from whole tablets due to bitter taste.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062828\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules: Gallbladder stone dissolution for patients with radiolucent, noncalcified gallbladder stones less than 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk caused by systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery (FDA approved in adults); prevention of gallstone formation in obese patients experiencing rapid weight loss (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Treatment of primary biliary cirrhosis (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used to facilitate bile excretion in infants with biliary atresia; treat cholestasis secondary to parenteral nutrition (PN); aid fat absorption in cystic fibrosis-related liver disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10579627\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ursodiol may be confused with ulipristal</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232681\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Constipation, diarrhea, dyspepsia, nausea, peptic ulcer, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Cholecystitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthritis, back pain, musculoskeletal pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchitis, cough, flu-like symptoms, pharyngitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal distress, abdominal pain, abnormal hepatic function tests, angioedema, anorexia, biliary colic, esophagitis, facial edema, fever, hepatobiliary disease, increased gamma-glutamyl transferase, increased liver enzymes, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, jaundice, laryngeal edema, malaise, metallic taste, myalgia, peripheral edema, pruritus, transaminases increased, urticaria, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232624\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ursodiol or any component of the formulation; not to be used with calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment stones; patients with unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula; allergy to bile acids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Aadditional contraindications (not in US labeling): Complete biliary obstruction of extrahepatic origin; widespread intrahepatic obstruction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232607\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concerns related to adverse effects:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Biliary obstruction:  Maintain bile flow during therapy to prevent biliary obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Use with caution in patients with chronic liver disease; monitor liver function tests monthly for the first 3 months, and every 6 months thereafter or as clinically necessary. Discontinuation of therapy may be necessary with significant elevations in liver function tests. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Gallbladder stone dissolution may take several months of therapy; complete dissolution may not occur and recurrence of stones within 5 years has been observed in up to 50% of patients. Patients should be cautiously selected for therapy, consider alternative treatments. Specific treatments should be initiated in patients with ascites, hepatic encephalopathy, variceal bleeding, or if an urgent liver transplant is necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nonvisualizing gallbladder: Use with caution in patients with a nonvisualizing gallbladder; therapy should be discontinued if gallbladder nonvisualization occurs during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300198\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223602\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12872&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: May decrease the serum concentration of Ursodiol. Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of Ursodiol. Management: Administer ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the therapeutic effect of Ursodiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May diminish the therapeutic effect of Ursodiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitrendipine: Ursodiol may decrease the absorption of Nitrendipine.  Management: Consider therapeutic alternatives.  If concomitant therapy cannot be avoided, avoid simultaneous administration.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232614\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13966873\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Ursodiol (ursodeoxycholic acid) is the treatment of choice for intrahepatic cholestasis of pregnancy (Kremer, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062825\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic disease: Monitor liver function tests (GGT, AST, ALT, bilirubin, and alkaline phosphatase) monthly for the first 3 months and every 6 months thereafter or as clinically necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gallbladder disease: ALT, AST, sonogram</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232606\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Decreases the cholesterol content of bile and bile stones by reducing the secretion of cholesterol from the liver and the fractional reabsorption of cholesterol by the intestines. Mechanism of action in primary biliary cirrhosis is not clearly defined.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232623\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: 90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~70%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Undergoes extensive enterohepatic recycling; following hepatic conjugation and biliary secretion, the drug is hydrolyzed to active ursodiol, where it is recycled or transformed to lithocholic acid by colonic microbial flora; during chronic administration, ursodiol becomes a major biliary and plasma bile acid constituting 30% to 50% of biliary and plasma bile acids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces; urine (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232622\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>60 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 60 mg/mL ursodiol oral suspension may be made with capsules. Empty the contents of twelve 300 mg capsules into a mortar. Add small portions of glycerin and mix to a uniform paste; mix while adding simple syrup in incremental proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 35 days refrigerated (Johnson 1995).</p>\n    <div class=\"reference\">Johnson CE, Nesbitt J. Stability of ursodiol in an extemporaneously compounded oral liquid. <i>Am J Health Syst Pharm.</i> 1995;52(16):1798-1800.<span class=\"pubmed-id\">8528836</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>20 mg/mL Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 20 mg/mL ursodiol oral suspension may be made with capsules and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of methylcellulose 1% and syrup NF. Empty the contents of seventeen 300 mg capsules into a mortar. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 255 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 255 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 91 days refrigerated (Nahata 1999).</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, Hipple TF. Stability of ursodiol in two extemporaneously prepared oral suspensions. <i>J Appl Ther Res. </i>1999;2:221-224.</div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>25 mg/mL Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 25 mg/mL ursodiol oral suspension may be made with capsules. Empty the contents of ten 300 mg capsules into a mortar; add 10 mL Glycerin, USP and mix until smooth. Mix while adding 60 mL Ora-Plus; transfer mixture to a light-resistant bottle, rinse mortar with a small amount of Orange Syrup, NF, and add quantity of syrup sufficient to make 120 mL. Label &quot;shake well&quot;. Stable for 60 days at room temperature or refrigerated (Mallett 1997).</p>\n    <div class=\"reference\">Mallett MS, Hagan RL, Peters DA. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid. <i>Am J Health Syst Pharm.</i> 1997;54(12):1401-1404.<span class=\"pubmed-id\">9194984</span></div>\r\n\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>50 mg/mL Oral Suspension</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A 50 mg/mL ursodiol oral suspension may be made with tablets and 60 mL of either a 1:1 mixture of Ora-Plus and strawberry syrup or a 1:1 mixture of Ora-Plus and Ora-Sweet SF. Crush twelve 250 mg tablets in a mortar and reduce to a fine powder. Add small portions of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost</b> 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 90 days refrigerated (Johnson 2002).</p>\n    <div class=\"reference\">Johnson CE, Streetman DD. Stability of oral suspensions of ursodiol made from tablets. <i>Am J Health Syst Pharm.</i> 2002;59(4):361-363.<span class=\"pubmed-id\">11885400</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232626\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Actigall Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $1,141.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ursodiol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $735.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Ursodiol+SyrSpend SF PH4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/mL (120 mL): $328.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Urso 250 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $630.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Urso Forte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $1,116.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ursodiol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $268.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $475.34</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F232628\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actigall (NZ);</li>\n      <li>Adursal (FI);</li>\n      <li>Canlin (TW);</li>\n      <li>Destolit (MT);</li>\n      <li>Deursil (IT);</li>\n      <li>Dexo (PY);</li>\n      <li>Estazor (ID);</li>\n      <li>Homan (VN);</li>\n      <li>Lupible (PH);</li>\n      <li>Taurolite (CN);</li>\n      <li>Triptor (LK);</li>\n      <li>Udihep (LK, TH);</li>\n      <li>Urdafalk (ID);</li>\n      <li>Urdek (ID);</li>\n      <li>Urosan (JP);</li>\n      <li>Ursa (JO, PH);</li>\n      <li>Ursacol (BR, CO, IT);</li>\n      <li>Ursilon (VN);</li>\n      <li>Urso (IN, LK);</li>\n      <li>Ursobilane (ES);</li>\n      <li>Ursocel (EC);</li>\n      <li>Ursochol (BE, CH, ES, ID, IS, LU, NL, NO);</li>\n      <li>Ursodamor (IT);</li>\n      <li>Ursodox (LK, PH);</li>\n      <li>Ursofalk (AE, AR, AT, AU, BG, CL, CN, CO, CR, CY, CZ, DE, EE, EG, GR, GT, HK, HN, HR, HU, IE, IL, KR, KW, LB, LU, MT, MX, MY, NI, NZ, PA, PE, PH, PK, PT, QA, RO, SA, SE, SI, SK, SV, TH, TR, UY);</li>\n      <li>Ursolic (TW);</li>\n      <li>Ursolin (TH);</li>\n      <li>Ursolit (IL);</li>\n      <li>Ursoliv (PH);</li>\n      <li>Ursolvan (FR);</li>\n      <li>Ursopol (PL);</li>\n      <li>Ursosan (JP, RU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Actigall capsules (ursodiol) [prescribing information]. Corona, CA: Watson Pharma, Inc; March 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arslanoglu S, Moro GE, Tauschel HD, Boehm G. Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. <i>J Pediatr Gastroenterol Nutr.</i> 2008;46(2):228-231.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/18223390/pubmed\" target=\"_blank\" id=\"18223390\">18223390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen CY, Tsao PN, Chen HL, Chou HC, Hsieh WS, Chang MH. Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. <i>J Pediatr.</i> 2004;145(3):317-321.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/15343182/pubmed\" target=\"_blank\" id=\"15343182\">15343182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colombo C, Setchell KD, Podda M, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. <i>J Pediatr.</i> 1990;117(3):482-489.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/2391610/pubmed\" target=\"_blank\" id=\"2391610\">2391610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. <i>J Cyst Fibros.</i> 2011;10 Suppl 2:S29-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/21658639/pubmed\" target=\"_blank\" id=\"21658639\">21658639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Marco G, Sordino D, Bruzzese E, et al. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. <i>Aliment Pharmacol Ther</i>. 2006;24(2):387-394.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/16842466/pubmed\" target=\"_blank\" id=\"16842466\">16842466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. <i>Turk J Pediatr.</i> 1999;41(1):91-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/10770681/pubmed\" target=\"_blank\" id=\"10770681\">10770681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gokmen T, Oguz SS, Bozdag S, Erdeve O, Uras N, Dilmen U. A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. <i>J Perinatol.</i> 2012;32(2):123-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/21566568/pubmed\" target=\"_blank\" id=\"21566568\">21566568</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly DA, Davenport M. Current management of biliary atresia. <i>Arch Dis Child.</i> 2007;92(12):1132-1135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/17878208/pubmed\" target=\"_blank\" id=\"17878208\">17878208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. <i>Clin Res Hepatol Gastroenterol.</i> 2011;35(2):89-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/21809485/pubmed\" target=\"_blank\" id=\"21809485\">21809485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lepage G, Paradis K, Lacaille F, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. <i>J Pediatr.</i> 1997;130(1):52-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9003851/pubmed\" target=\"_blank\" id=\"9003851\">9003851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L. Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. <i>J Pediatr Endocrinol Metab.</i> 1999;12(4):549-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/10417972/pubmed\" target=\"_blank\" id=\"10417972\">10417972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyers RL, Books LS, O&rsquo;Gorman MA, et al. High-dose steroids, ursodeoxycholic acid, and chronic intravenous antibiotics improve bile flow after Kasai procedure in infants with biliary atresia. <i>J Pediatr Surg.</i> 2003;38(3):406-411.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/12632357/pubmed\" target=\"_blank\" id=\"12632357\">12632357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. <i>J Pediatr Gastroenterol Nutr.</i> 1998;26(1):49-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9443120/pubmed\" target=\"_blank\" id=\"9443120\">9443120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nittono H, Tokita A, Hayashi M, et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. <i>Biomed Pharmacother</i>. 1989;43(1): 37-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/2730950/pubmed\" target=\"_blank\" id=\"2730950\">2730950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. <i>Eur J Clin Invest.</i> 2000;30(2): 135-139.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/10651838/pubmed\" target=\"_blank\" id=\"10651838\">10651838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sokol RJ, Durie PR. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. <i>J Pediatr Gastroenterol Nutr.</i> 1998;Suppl 1:S1-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/9934970/pubmed\" target=\"_blank\" id=\"9934970\">9934970</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. <i>Gastroenterology.</i> 1996;111(3):717-719.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/8780577/pubmed\" target=\"_blank\" id=\"8780577\">8780577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stringer MD, Davison SM, Rajwal SR, McClean P. Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen. <i>J Pediatr Surg.</i> 2007;42(8):1324-1328.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/17706489/pubmed\" target=\"_blank\" id=\"17706489\">17706489</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ullrich D, Rating D, Schroter W, Hanefeld F, Bircher J. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. <i>Lancet.</i> 1987;2(8571):1324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/2890915/pubmed\" target=\"_blank\" id=\"2890915\">2890915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urso tablets (ursodiol) [prescribing information]. Bridgewater, NJ: Aptalis Pharma US, Inc; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yamashiro Y, Ohtsuka Y, Shimizu T. Effects of ursodeoxycholic acid treatment on essential fatty acid deficiency in patients with biliary atresia. <i>J Pediatr Surg.</i> 1994;29(3):425-428.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ursodeoxycholic-acid-ursodiol-pediatric-drug-information/abstract-text/8201513/pubmed\" target=\"_blank\" id=\"8201513\">8201513</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12872 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F232635\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F232636\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062826\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445212\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062819\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F232618\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F232603\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50027245\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062829\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F232632\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062828\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10579627\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F232681\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F232624\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F232607\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300198\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223602\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F232614\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13966873\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062825\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F232606\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F232623\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F232622\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F232626\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F232628\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12872|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ursodeoxycholic-acid-ursodiol-drug-information\" class=\"drug drug_general\">Ursodeoxycholic acid (ursodiol): Drug information</a></li><li><a href=\"topic.htm?path=ursodeoxycholic-acid-ursodiol-patient-drug-information\" class=\"drug drug_patient\">Ursodeoxycholic acid (ursodiol): Patient drug information</a></li></ul></div></div>","javascript":null}